Neurocrine Biosciences (NBIX) closed at $146.00 on October 27, 2026, up 0.1% from the previous close, on volume of 1,061,753 shares (30-day average 1,322,830).
Data as of October 27, 2026.
Healthcare stocks with strong revenue growth and attractive valuations
Seeking Alpha News (Tue, 27-Oct 7:10 AM ET)
PRNewswire (Mon, 26-Oct 8:31 AM ET)
PRNewswire (Thu, 22-Oct 4:05 PM ET)
Globe Newswire (Wed, 21-Oct 10:40 AM ET)
PRNewswire (Tue, 20-Oct 8:30 AM ET)
PRNewswire (Fri, 16-Oct 8:31 AM ET)
NBIX Sets Nov. 2 Timeline for Q3 2026 Results: Release at 4:00 p.m. ET, Call at 4:30 p.m. ET
Market Chameleon (Tue, 13-Oct 7:51 AM ET)
NBIX Sets Nov. 2 Timeline for Q3 2026 Results, With Webcast Replay Archived for About a Month
Market Chameleon (Tue, 13-Oct 4:19 AM ET)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
PRNewswire (Mon, 12-Oct 4:01 PM ET)
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Neurocrine Biosciences trades on the NASDAQ stock market under the symbol NBIX.
As of October 28, 2026, NBIX stock price declined to $145.48 with 173,448 million shares trading.
NBIX has a beta of 0.49, meaning it tends to be less sensitive to market movements. NBIX has a correlation of 0.03 to the broad based SPY ETF.
NBIX has a market cap of $14.63 billion. This is considered a Large Cap stock.
Last quarter Neurocrine Biosciences reported $959 million in Revenue and $2.85 earnings per share. This beat revenue expectation by $82 million and exceeded earnings estimates by $.75.
In the last 3 years, NBIX traded as high as $186.12 and as low as $84.23.
The top ETF exchange traded funds that NBIX belongs to (by Net Assets): IJH, VTI, VB, VBK, VXF.
NBIX has underperformed the market in the last year with a return of -2.3%, while the SPY ETF gained +13.5%. In the last 3 month period, NBIX fell short of the market, returning -17.5%, while SPY returned +4.5%. However, in the most recent 2 weeks NBIX has outperformed the stock market by returning +7.7%, while SPY returned -1.0%.
NBIX support price is $143.57 and resistance is $148.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBIX shares will trade within this expected range on the day.
